Thrombotic risks of oral contraceptives

Current Opinion in Obstetrics and Gynecology

Volumn 24, Issue 4, 2012, Pages 235-240

  Rott, Hannelore ^a  

^a Rhein Ruhr ^*  (Germany)

Author keywords

combined oral contraceptives; estradiovalerat; progestogen only contraceptive; thrombophilia; venous thromboembolism

Indexed keywords

1 AMINO 1,5 INDANDICARBOXYLIC ACID; 28 MINI; COMBINED ORAL CONTRACEPTIVE AGENT; CYPROTERONE ACETATE PLUS ETHINYLESTRADIOL; DEPO CLINOVIR; DESMIN; DESOGESTREL; DESOGESTREL PLUS ETHINYLESTRADIOL; DIENOGEST PLUS ESTRADIOL VALERATE; DIENOGEST PLUS ETHINYLESTRADIOL; DROSPIRENONE PLUS ETHINYLESTRADIOL; ESTRADIOL; ESTRADIOL PLUS NOMEGESTROL ACETATE; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS ETONOGESTREL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORELGESTROMIN; ETONOGESTREL; GESTAGEN; LEIOS; LEVOGYNON; LEVONORGESTREL; MAXIM; MEDROXYPROGESTERONE ACETATE; NEO EUNORMIN; NORETHISTERONE; NORETHISTERONE ENANTATE; ORAL CONTRACEPTIVE AGENT; SAYANA; ULIPRISTAL; UNCLASSIFIED DRUG; UNOFEM;

AGE; CARDIOVASCULAR RISK; DRUG CONTRAINDICATION; DRUG MEGADOSE; HORMONAL CONTRACEPTION; HORMONE SUBSTITUTION; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; MEDICAL HISTORY; MENORRHAGIA; PREGNANCY; PRIORITY JOURNAL; PUERPERIUM; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; VENOUS THROMBOEMBOLISM;

ADOLESCENT; ADULT; AGE FACTORS; CONTRACEPTIVES, ORAL, COMBINED; CONTRACEPTIVES, ORAL, HORMONAL; ETHINYL ESTRADIOL; EUROPE; FEMALE; HUMANS; INCIDENCE; MIDDLE AGED; RISK ASSESSMENT; RISK FACTORS; SMOKING; TIME FACTORS; VENOUS THROMBOEMBOLISM; YOUNG ADULT;

EID: 84863727978     PISSN: 1040872X     EISSN: 1473656X     Source Type: Journal    
DOI: 10.1097/GCO.0b013e328355871d     Document Type: Review

References (26)

1. Cohen AT, Agnelli G, Anderson FA, et al. Venous thromboembolism (VTE) in Europe The number of VTE events and associated morbidity and mortality. Thromb Haemost 2007; 98:756-764.
2. German guideline 'Contraception'. Deutsche Gesellschaft für Gynäkologie und Geburtshilfe. 2008. http://www.awmf.org/uploads/tx- szleitlinien/015-015.pdf.
3. Rabe T, Luxembourg B, Ludwig M, et al. 'Contraception and Thrombophilia: a statement from the German Society for Gynecological Endocrinology and Reproductive Medicine (DGGEF e.V.) and the Professional Association of German Gynaecologists (BVF e.V.). J Reproduktionsmed Endokrinol 2011; 8:178-218.
4. Vlijmen EFW van, Veeger NJGM, Middeldorp S, et al. Thrombotic risk during oral contraceptive use and pregnancy in women with factor V Leiden or prothrombin mutation: a rational approach to contraception. Blood 2011; 118:2055-2061.
5. Herings RM, Urquhart J, Leufkens HG. Venous thromboembolism among new users of different oral contraceptives. Lancet 1999; 354:127-128.
6. Kemmeren JM, Algra A, Grobbee DE. Third generation orals contraceptives and risk of venous thrombosis: meta-analysis. BMJ 2001; 323:131-134.
7. German S3-guideline: 'Prophylaxis of venous thromboembolism' 2009: http://www.awmf.org/uploads/tx-szleitlinien/003-001l-S3-VTE-Prophylaxe- 2010.pdf.
8. Barkfeldt J, Virkkunen A, Dieben T. The effects of two progestogen-only pills containing either desogestrel (75 microg/day) or levonorgestrel (30 microg/day) on lipid metabolism. Contraception 2001; 64:295-299.
9. Hughes Q, Watson M, Cole V, et al. Upregulation of protein S by progestins. J Thromb Haemost 2007; 5:2243-2249.
10. Royal College of Obstetricians and Gynaecologists (RCOG). Venous thromboembolism and hormonal contraception. Guideline No. 40. London: RCoG 2004; 13.
11. van Vliet HA, Bertina RM, Dahm AE, et al. Different effects of oral contraceptives containing different progestogens on protein s and tissue factor pathway inhibitor. J Thromb 2008; 6:346-351.
12. Winkler UH, Howie H, Buhler K, et al. A randomized controlled double-blind study of the effects on hemostasis to two progeston-only pills containing 75mg desogestrel or 30 mg levonorgestrel. Contraception 1998; 57:385-392.
13. van Hylckama Vlieg A, Helmerhors FM, Vandenbroucke JP, et al. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA-case control study. BMJ 2009; 339:b2921.
14. Klipping C, Duijkers I, Parke S, et al. Hemostatic effects of a novel estradiolbased oral contraceptive: an open-label, randomized, crossover study of estradiol valerate/dienogest versus ethinylestradiol/levonorgestrel. Drugs 2011; 11:159-170.
15. Junge W, Mellinger U, Parke S, et al. Metabolic and haemostatic effects of estradiol valerate/dienogest, a novel oral contraceptive: a randomized, open-label, single-centre study. Clin Drug Investig 2011; 31:573-584.
16. Ågren UM, Anttila M, Mäenpää-Liukko K, et al. Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17boestradiol compared with one containing levonorgestrel and ethinylestradiol on haemostasis, lipids and carbohydrate metabolism. Eur J Contracept Reprod Health Care 2011; 16:444-457.
17. Gaussem P, Alhenc-Gelas M, Thomas J-L, et al. Haemostatic effects of a new combined oral contraceptive, nomegestrol acetate/17b-estradiol, compared with those of levonorgestrel/ethinyl estradiol. A double-blind, randomised study. Thromb Haemost 2011; 105:560-567.
18. Sitruk-Ware R, Plu-Bureau G, Menard J, et al. Effects of oral and transvaginal ethinyl estradiol on hemostatic factors and hepatic proteins in a randomized, crossover study. J Clin Endocrinol Metab 2007; 92:2074-2079.
19. Jick SS, Kaye JA, Russmann S, et al. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol. Contraception 2006; 73:223-228.
20. World Health Organization. Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Contraception 1998; 57:315-324.
21. van Hylckama Vlieg JE, Helmerhorst FM, Rosendaal FR. The risk of deep venous thrombosis associated with injectable depot-medroxyprogesterone acetate contraceptives or a levonorgestrel intrauterine device. Arterioscler Thromb Vasc Biol 2010; 30:2297-2300.
22. Meirik O, Farley TM, Sivin I, for the International Collaborative Postmarketing Surveillance of Norplant. Safety and efficacy of levonorgestrel implant, intrauterine device, and sterilization. Obstet Gynaecol 2001; 97:539-547.
23. Vasilakis C, Jick H, del Mar Melero-Montes M. Risk of idiopathic venous thromboembolism in users of progestagens alone. Lancet 1999; 354:1610-1611.
24. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. A multinational case-control study of cardiovascular disease and steroid hormone contraceptives. J Clin Endocrinol Metab 1995; 48:1513-1547.
25. Poulter NR, Chang CL, Farley TM, Meirik O. Risk of cardiovascular diseases associated with oral progestogen preparations with therapeutic indications. Lancet 1999; 354:1610.
26. WHO Medical eligibility criteria for contraceptive use. 2008 update. http://whqlibdoc.who.int/publications/2010/9789241563888-eng.pdf.